Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Clinical Oncology (ASCO)
ASCO 2019 – CLL
ASCO 2019 – CLL
Conceptual Model of CLL
ASCO 2019 – CLL
Researchers created a conceptual model of chronic lymphocytic leukemia (CLL) to elucidate patient perceptions of disease symptoms and impacts. The findings are expected to help define patient-centered end points in future clinical studies.
Read More ›
Effect of Dose Modifications on Response to Duvelisib in Patients with Relapsed/Refractory CLL/SLL in the DUO Trial
ASCO 2019 – CLL
This post hoc tolerability analysis of duvelisib found that dose interruptions or reductions did not adversely affect response to treatment for most patients.
Read More ›
Final Analysis from RESONATE: Six-Year Follow-Up in Patients with Previously Treated CLL/SLL Receiving Ibrutinib
ASCO 2019 – CLL
Long-term follow-up of patients receiving ibrutinib showed sustained efficacy, low rates of discontinuation, and acceptable tolerability with no new safety signals over time. This analysis provides additional evidence supporting ibrutinib as standard of care in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL).
Read More ›
A Phase 2 Study Investigating Umbralisib Monotherapy in Patients with Relapsed/Refractory MZL
ASCO 2019 – CLL
In a phase 2 study, the next-generation PI3Kδ inhibitor umbralisib demonstrated efficacy and safety when given as monotherapy in patients with relapsed or refractory marginal zone lymphoma (MZL).
Read More ›
The ZUMA-8 Phase 1/2 Multicenter Study Evaluating KTE-X19 in Patients with Relapsed/Refractory CLL
ASCO 2019 – CLL
In prior research, chimeric antigen receptor (CAR) T-cell therapy has shown encouraging clinical activity in hematologic malignancies. The study design for the ZUMA-8 phase 1/2 trial evaluating the investigational CAR T-cell therapy KTE-X19 was presented at the ASCO 2019 Annual Meeting.
Read More ›
Phase 1/2 Trial of Cirmtuzumab plus Ibrutinib: Planned Analysis of Phase 1 CLL Cohorts
ASCO 2019 – CLL
The phase 1 portion of a clinical trial combining the novel monoclonal antibody cirmtuzumab with ibrutinib yielded promising results, and investigators will move forward with the phase 2 portion of the trial.
Read More ›
Ibrutinib Maintenance Following Induction for Untreated MCL: Initial Safety Report
ASCO 2019 – CLL
At 19 months of follow-up, ibrutinib maintenance in mantle-cell lymphoma (MCL) shows promising efficacy with acceptable tolerability. Future reports are expected to provide additional insight into this potential new option for MCL maintenance therapy after induction.
Read More ›
SYK Inhibition with Fostamatinib in Waldenström’s Macroglobulinemia
ASCO 2019 – CLL
Preclinical studies show that the spleen tyrosine kinase (SYK) inhibitor R406 exhibits a mechanism of action that makes it a logical target for clinical exploration in Waldenström’s macroglobulinemia.
Read More ›
A Systematic Review of the Efficacy of Ibrutinib-Based Combination Therapy for Mantle-Cell Lymphoma
ASCO 2019 – CLL
A systematic review of 11 studies found that ibrutinib is effective and well-tolerated when administered in combination with a range of other therapeutic agents for the treatment of patients with mantle-cell lymphoma.
Read More ›
Effect of Fixed-Duration Venetoclax plus Obinutuzumab on Progression-Free Survival and Minimal Residual Disease Status in Treatment-Naïve Patients with CLL and Comorbidities
ASCO 2019 – CLL
Recent data from the phase 3 CLL14 trial indicate that a combination of venetoclax plus obinutuzumab, given as fixed-duration therapy, showed impressive and sustained MRD-negative rates, translating into improved progression-free survival.
Read More ›
Page 1 of 2
1
2
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us